Article Text

PDF

Managing asthma: inhaled therapy and beyond
P110 Fluticasone propionate/formoterol fumarate combination therapy is more efficacious in improving lung function than its individual components in patients with asthma
  1. D Price1,
  2. A Papi2,
  3. K Kaiser3,
  4. B Grothe4,
  5. M Lomax4,
  6. T McIver4
  1. 1Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
  2. 2University of Ferrara, Ferrara, Italy
  3. 3SkyePharma, Muttenz, Switzerland
  4. 4Mundipharma Research Limited, Cambridge, UK

Abstract

Introduction and Objectives Combination therapy with an inhaled corticosteroid (ICS) and a long-acting ß2-agonist (LABA) is the most effective treatment option for patients with asthma uncontrolled with ICS monotherapy.1 In practice, asthma symptoms remain uncontrolled or only partly controlled in many patients. A new therapy option for asthma combining the ICS fluticasone propionate (FLUT) and the LABA formoterol fumarate (FORM) in a single aerosol inhaler (FLUT/FORM; flutiform®), has been developed at doses of 100/10, 250/10 and 500/20 μg for twice-daily administration. In this analysis, data were pooled from up to five randomised, double-blind, parallel-group studies in order to assess the efficacy of FLUT/FORM in terms of improvement in lung function (as indicated by change in FEV1).

Methods The analysis included adults and adolescents with a range of asthma severities who were treated for 8 or 12 weeks with FLUT/FORM (100/10, 250/10 or 500/20 μg twice daily) or the equivalent nominal dose of FLUT monotherapy (100, 250 or 500 μg twice daily; five studies) or FORM monotherapy (10 μg twice daily; three studies).

Results FLUT/FORM was associated with a significantly greater improvement in lung function, as indicated by change in FEV1, compared with its individual components (Abstract P110 table 1). FLUT/FORM was superior to FORM with regard to change in pre-dose FEV1 from baseline to study end; the least-squares (LS) mean difference for FLUT/FORM vs FORM was 0.13 l (95% CI 0.07 to 0.19; p<0.001). Similarly, FLUT/FORM was superior to FLUT with regard to change in FEV1 from pre-dose at baseline to 2 h post-dose at study end (LS mean difference FLUT/FORM vs FLUT 0.15 L [95% CI 0.10 to 0.19; p<0.001]).

Abstract P110 Table 1

Conclusions The combination of fluticasone/formoterol in a single aerosol inhaler is more effective than fluticasone or formoterol given alone in improving lung function for patients with a range of asthma severities.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.